RASL11B

Across TCGA pan-cancer cohorts, RASL11B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RASL11B data layer compared with 27 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher RASL11B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RASL11B expression acts as an unfavorable survival marker.

LUSC and STAD are the cancer types where RASL11B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.139	0.663	.027	6	view →
STAD	OS	Median	All	0.250	0.729	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RASL11B–LUSC (DFS)

Open the LUSC breakdown →